A dose determination program for an erythropoiesis-stimulating agent that is executable by a computer. The program causes the computer to perform: obtaining a predetermined target hemoglobin concentration; obtaining a first concentration and a first dose in a stable state in which a hemoglobin concentration is stable at the first concentration by repeatedly administering the first dose a plurality of times, and calculating a second dose of the erythropoiesis-stimulating agent based on the obtained target hemoglobin concentration, the obtained first concentration, and the obtained first dose, the second dose of the erythropoiesis-stimulating agent being to be administered by a fixed amount.

Disclosed are polypeptides comprising an engineered recombinant EPO. For example, disclosed are polypeptides comprising the sequence of SEQ ID NO: 1. Disclosed are variant Epo polypeptides comprising three amino acid substitutions at positions 20, 45 and 97 of wild type human Epo. Disclosed are polynucleotides comprising a nucleic acid capable of encoding one or more of the disclosed polypeptides. Disclosed are vectors comprising any of the polynucleotides disclosed herein. Disclosed are compositions comprising the disclosed polypeptides, polynucleotides or vectors. Disclosed are cells comprising one or more of the disclosed polypeptides, one or more of the disclosed polynucleotides, and/or one or more of the disclosed vectors. Disclosed are methods of using a therapeutically effective amount of one or more of the disclosed polypeptides, nucleic acids or vectors to a subject in need thereof.

Disclosed are polypeptides comprising an engineered recombinant EPO. For example, disclosed are polypeptides comprising the sequence of SEQ ID NO: 1. Disclosed are variant Epo polypeptides comprising three amino acid substitutions at positions 20, 45 and 97 of wild type human Epo. Disclosed are polynucleotides comprising a nucleic acid capable of encoding one or more of the disclosed polypeptides. Disclosed are vectors comprising any of the polynucleotides disclosed herein. Disclosed are compositions comprising the disclosed polypeptides, polynucleotides or vectors. Disclosed are cells comprising one or more of the disclosed polypeptides, one or more of the disclosed polynucleotides, and/or one or more of the disclosed vectors. Disclosed are methods of using a therapeutically effective amount of one or more of the disclosed polypeptides, nucleic acids or vectors to a subject in need thereof.

The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.

The present specification discloses a pharmaceutical composition or stable aqueous formulations for erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, and methods and uses of erythropoietin receptor agonists and compositions. The present specification further discloses medicaments for treating an anemia in non-human mammals such as cats.

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.

The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.

The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.